Search

Jiaxin Hu

from Coppell, TX
Age ~56
Get Report
Also known as:
Jiazi Hu, Hu Jiaxin, N Hu
Phone and address:
920 Mill Trl, Coppell, TX 75019
Connected to:
Caifeng Hu, 63Chenghao Hu, 58Cheung P Hu, 51Dominic H Hu, 71Hongye Hu, 40Hsun M Hu, 61Huijuan Hu, 63Iva Hu, 29Jak Hu, 62Laurie H Hu, 77

Jiaxin Hu Phones & Addresses

  • 920 Mill Trl, Coppell, TX 75019
  • 6401 Maple Ave, Dallas, TX 75235 (214) 353-0368 (214) 353-2959
  • Plano, TX
  • 5041 Waterman Ave, Saint Louis, MO 63108
  • Clayton, MO

Work

Company: Ut southwestern medical center at dallas Position: Instructor

Industries

Hospital & Health Care

Resumes

Resumes

Jiaxin Hu Photo 1

Instructor

View page
Location:
Coppell, TX
Industry:
Hospital & Health Care
Work:
Ut Southwestern Medical Center at Dallas
Instructor

Publications

Us Patents

Selective Inhibition Of Polyglutamine Protein Expression

View page
US Patent:
20130172399, Jul 4, 2013
Filed:
Feb 3, 2011
Appl. No.:
13/575842
Inventors:
David R. Corey - Dallas TX, US
Jiaxin Hu - Dallas TX, US
Dinah W.Y. Sah - Hopkinton MA, US
International Classification:
C12N 15/113
US Classification:
514 44 A, 536 245, 435375
Abstract:
The present invention relates to the selective inhibition of protein expression of CAG repeat-related disease proteins such as Huntingtin Disease Protein and Ataxin-3 using double-stranded RNAs and nucleic acid analogs. Chemically-modified RNAs having at least one mismatch as compared to the target CAG repeat sequence are specifically contemplated.

Selective Inhibition Of Polyglutamine Protein Expression

View page
US Patent:
20110190222, Aug 4, 2011
Filed:
Jul 28, 2009
Appl. No.:
13/056556
Inventors:
David R. Corey - Dallas TX, US
Jiaxin Hu - Coppell TX, US
Masayuki Matsui - Irving TX, US
International Classification:
A61K 38/02
A61K 31/7088
C07H 21/00
C07K 2/00
A61P 25/00
A61P 25/28
US Classification:
514 209, 514 44 A, 514 11, 536 245, 530300
Abstract:
The present invention relates to the selective inhibition of protein expression of CAG repeat-related disease proteins such as Huntingtin using nucleic acid analogs. Peptide nucleic acids and locked nucleic acids are particularly useful analogs.

Molecular Biomarkers And Targets For Fuches' Endothelial Corneal Dystrophy And Glaucoma

View page
US Patent:
20210348234, Nov 11, 2021
Filed:
Feb 24, 2021
Appl. No.:
17/184360
Inventors:
- Austin TX, US
David R. COREY - Dallas TX, US
Jiaxin HU - Coppell TX, US
Yongjun CHU - Dallas TX, US
Assignee:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM - Austin TX
International Classification:
C12Q 1/6883
Abstract:
Molecular biomarkers relating to Fuchs' endothelial corneal dystrophy (FECD), glaucoma, and other degenerative ocular diseases are provided, as well as methods for using such biomarkers methods of treatment. These biomarkers may be used to monitor the progression of FECD, glaucoma, or other degenerative ocular diseases. Furthermore, these biomarkers may be used to monitor the treatment of FECD, glaucoma, or other degenerative ocular diseases.

Treatment Of Fuchs' Endothelial Corneal Dystrophy

View page
US Patent:
20210139894, May 13, 2021
Filed:
Mar 9, 2018
Appl. No.:
16/492522
Inventors:
- Austin TX, US
- Boston MA, US
Jiaxin HU - Coppell TX, US
Jonathan K. WATTS - Worcester MA, US
Assignee:
The Board of Regents of the University of Texas System - Austin TX
University of Massachusetts - Boston MA
International Classification:
C12N 15/113
A61K 31/7105
A61K 9/00
C12N 15/11
Abstract:
Described are compounds and methods useful in the treatment of Fuchs' Endothelial Corneal Dystrophy (FECD).

Allele Selective Inhibition Of Mutant C9Orf72 Foci Expression By Duplex Rnas Targeting The Expanded Hexanucleotide Repeat

View page
US Patent:
20200208154, Jul 2, 2020
Filed:
Jan 10, 2020
Appl. No.:
16/739654
Inventors:
- Austin TX, US
Jiaxin HU - Coppell TX, US
Assignee:
The Board of Regents of the University of Texas System - Austin TX
International Classification:
C12N 15/113
A61K 31/713
Abstract:
Provided herein are compositions and methods for reducing expression of C9orf72 transcripts in cells containing expanded intronic GGGGCC regions, including those in subjects having or at risk of developing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Allele Selective Inhibition Of Mutant C9Orf72 Foci Expression By Duplex Rnas Targeting The Expanded Hexanucleotide Repeat

View page
US Patent:
20170233735, Aug 17, 2017
Filed:
Oct 8, 2015
Appl. No.:
15/518824
Inventors:
- Austin TX, US
Jiaxin HU - Coppell TX, US
International Classification:
C12N 15/113
A61K 31/713
Abstract:
Provided herein are compositions and methods for reducing expression of C9orf72 transcripts in cells containing expanded intronic GGGGCC regions, including those in subjects having or at risk of developing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Provided herein are a double-stranded oligonucleotides of 13 to 22 nucleobases in length targeting a GGGGCC expanded repeat region in an intron of C9orf72, comprises (a) 3-5 central mismatches (within bases 9-14) within a target sequence comprising the expanded repeat sequence, or (h) 3-5 mismatches outside of the seed sequence (bases 2-8 within the guide strand complementary to the expanded repeat sequence).

Selective Inhibition Of Polyglutamine Protein Expression

View page
US Patent:
20150211007, Jul 30, 2015
Filed:
Nov 3, 2014
Appl. No.:
14/531203
Inventors:
- Austin TX, US
Jiaxin HU - Coppell TX, US
Masayuki MATSUI - Irving TX, US
Assignee:
The Board of Regents of the University of Texas System - Austin TX
International Classification:
C12N 15/113
Abstract:
The present invention relates to the selective inhibition of protein expression of CAG repeat-related disease proteins such as Huntington using nucleic acid analogs. Peptide nucleic acids and locked nucleic acids are particularly useful analogs.

Oligonucleotide Modulation Of Splicing

View page
US Patent:
20140128449, May 8, 2014
Filed:
Mar 23, 2012
Appl. No.:
14/009745
Inventors:
Jing Liu - Dallas TX, US
Jiaxin Hu - Dallas TX, US
David R. Corey - Dallas TX, US
Assignee:
The Board of Regents of the University of Texas System - Austin TX
International Classification:
C12N 15/113
US Classification:
514 44 A, 435375, 536 245
Abstract:
The present invention relates to the selective modulation of pre-mRNA splicing, in particular, for that involving alternative splicing in disease-related proteins such as those involved in Duschenne's Muscular Dystropy and Spinal Muscular Atrophy.
Control profile
Jiaxin Hu from Coppell, TX, age ~56 Get Report